However, the response rate in the above studies was not absolute; to advance the effect of IFN-α/5-FU combination therapy and to increase the response rate, it is necessary to investigate the mechanism and to predict the response to IFN-α/5-FU combination therapy, for patients with advanced HCC. This evidence concerns the gene IFNA1 and hepatocellular carcinoma.